Podchaser Logo
Home
Critical questions for a melanoma pathologist

Critical questions for a melanoma pathologist

Released Monday, 27th June 2022
Good episode? Give it some love!
Critical questions for a melanoma pathologist

Critical questions for a melanoma pathologist

Critical questions for a melanoma pathologist

Critical questions for a melanoma pathologist

Monday, 27th June 2022
Good episode? Give it some love!
Rate Episode

The role of pathology in the diagnosis and treatment of melanoma is pivotal to optimal patient care. With so many disciplines relying on the pathologist for accurate diagnoses and critical pathological information, we decided to reach out to our clinical melanoma community to ask them for their critical pathology questions. 

In this podcast, Prof John Thompson AO and Prof Fergal Moloney pick at the brain of the world's leading melanoma Pathologist, Prof Richard Scolyer AO, as they discuss: 

  • The clinical information needed to aid diagnosis 
  • The role of artificial intelligence and computing in pathology 
  • Overdiagnosis of melanoma 
  • The problem of partial biopsies 
  • Diagnosing borderline lesions 
  • What is a melanocytoma and how should it be managed 
  • What is an irritated naevus 
  • Dysplastic naevi and appropriate management 

This podcast is suitable for GPs, Dermatologists, Surgeons, Oncologists, Pathologists and other healthcare professionals. 

SPEAKERS 

Prof Richard Scolyer AO - Co-Medical Director, Melanoma Institute Australia | Pathologist, Melanoma Institute Australia, Senior Staff Specialist, Royal Prince Alfred Hospital | Clinical Professor, The University of Sydney 

Prof John Thompson AO - Emeritus Professor of Melanoma and Surgical Oncology, The University of Sydney | Member, Melanoma Institute Australia 

Prof Fergal Moloney - Consultant Dermatologist, Melanoma Institute Australia and Mater Misericordiae University Hospital | Clinical Professor, University College, Dublin 

Please note that this podcast was accurate at the time of recording (June 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. 

For more practice-changing education, visit our Melanoma Education Portal. 

MIA's Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb, Novartis and HEINE.

Show More

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features